OutSee has received a Discovery Award from the Longitude Prize on ALS, the genomics and drug discovery company has announced. 

The award will grant OutSee access to genomic data from 9,000 amyotrophic lateral sclerosis (ALS) patients, in addition to £100,000 ($134,000) in funding, supporting a research project to uncover novel therapeutic targets for ALS using OutSee’s proprietary ‘genomics first’ platform. 

The Longitude Prize on ALS is a competitive £7.5 million ($10 million) global challenge prize, aiming to leverage recent advances in AI-based discovery to uncover new therapeutic targets and effectively treat ALS, a fatal and progressive neurodegenerative disease that affects around one in 300 people throughout their lifetimes. 

The Longitude Prize provides companies with access to the world’s largest ALS patient dataset, combining biological information from a large array of global sources, available together for the first time. This includes whole genome sequence data from 9,000 ALS patients, combined with epigenomic, transcriptomic, and proteomic data for over 2,000 cases, and supported by extensive neuroimaging and clinical data. 

The Discovery Award will allow OutSee to initiate a nine-month discovery project, using the company’s AI-driven platform, Nomaly, to analyse the ALS dataset. Once new dataset insights have been identified, OutSee says it will work with partners to provide disease-specific expertise and advance promising disease targets to the next stage of development. 

“We are excited to have been selected for a Discovery Award, which will enable us to access genomic data from ALS patients on an unprecedented scale,” said Dr Chang Lu, Chief Scientific Officer at OutSee. 

“We have already built a strong internal pipeline of targets in CNS diseases, and are confident that our breakthrough genomics platform and expertise in AI-driven target identification uniquely place OutSee to unlock new insights into the mechanisms that underpin ALS, and to translate those insights into valuable new therapeutic targets.”